Weekly Analysts’ Ratings Changes for OncoCyte (OCX)

A number of firms have modified their ratings and price targets on shares of OncoCyte (NASDAQ: OCX) recently:

• 11/8/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 11/2/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 10/27/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 10/21/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 10/15/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 10/15/2024 – OncoCyte had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $4.25 price target on the stock.
• 10/9/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 10/3/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 9/27/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 9/21/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 9/15/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 9/9/2024 – OncoCyte is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.

OncoCyte Price Performance

Shares of OCX traded up $0.01 on Friday, hitting $2.85. 19,649 shares of the stock traded hands, compared to its average volume of 35,812. The business has a 50 day simple moving average of $3.05 and a 200 day simple moving average of $2.96. OncoCyte Co. has a one year low of $2.29 and a one year high of $4.34.

OncoCyte (NASDAQ:OCX) last issued its earnings results on Thursday, August 8th. The company reported ($0.36) earnings per share (EPS) for the quarter. OncoCyte had a negative return on equity of 149.88% and a negative net margin of 3,558.46%. The company had revenue of $0.10 million during the quarter.

Insider Transactions at OncoCyte

In other OncoCyte news, major shareholder Broadwood Partners, L.P. purchased 1,315,339 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The shares were acquired at an average price of $2.95 per share, for a total transaction of $3,880,250.05. Following the purchase, the insider now directly owns 6,244,405 shares of the company’s stock, valued at $18,420,994.75. The trade was a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, major shareholder Broadwood Partners, L.P. bought 1,315,339 shares of the stock in a transaction that occurred on Wednesday, October 2nd. The shares were bought at an average price of $2.95 per share, for a total transaction of $3,880,250.05. Following the purchase, the insider now owns 6,244,405 shares in the company, valued at $18,420,994.75. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Andrea S. James bought 33,670 shares of the stock in a transaction that occurred on Wednesday, October 2nd. The shares were purchased at an average price of $2.97 per share, for a total transaction of $99,999.90. Following the purchase, the chief financial officer now owns 33,670 shares in the company, valued at $99,999.90. The disclosure for this purchase can be found here. Corporate insiders own 1.58% of the company’s stock.

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.